PMC:7299399 / 14895-15417
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T62 | 341-349 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T92 | 68-77 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T93 | 78-81 | Chemical | denotes | NPs | http://purl.obolibrary.org/obo/CHEBI_50803 |
| T94 | 114-127 | Chemical | denotes | cyclodextrins | http://purl.obolibrary.org/obo/CHEBI_23456 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T70 | 0-522 | Sentence | denotes | An example of this process is the recent redesign of broad-spectrum antiviral NPs into equally effective modified cyclodextrins.54 Moreover, nanotechnology may offer nanotheranostic approaches to fill the existing gap between diagnostics and therapy.55−57 The simultaneous management of both diagnostics and therapy for those suffering from COVID-19 or in future pandemics, as for many other diseases, is an additional potential strategy to take into consideration in which nanomaterials have proven to be effective tools. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 243 | 114-127 | Chemical | denotes | cyclodextrins | MESH:D003505 |
| 245 | 341-349 | Disease | denotes | COVID-19 | MESH:C000657245 |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32519842-32064341-158481 | 128-130 | 32064341 | denotes | 54 |
| 32519842-32031781-158482 | 250-252 | 32031781 | denotes | 55 |
| 32519842-32373222-158483 | 253-255 | 32373222 | denotes | 57 |